3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Prostatic Neoplasms
17
Urinary Bladder Neoplasms
10
Kidney Neoplasms
6
Pancreatic Neoplasms
4
Neoplasms
4
Head and Neck Neoplasms
4
Ovarian Neoplasms
3
Neoplasm Metastasis
3
Melanoma
3
Lung Neoplasms
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Wilms Tumor
2
Uterine Cervical Neoplasms
2
Testicular Neoplasms
2
Stomach Neoplasms
2
Skin Neoplasms
2
Sarcoma
2
Muscle-invasive Bladder Cancer
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Liver Neoplasms
2
Laryngeal Neoplasms
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Cholangiocarcinoma
2
Central Nervous System Neoplasms
2
Carcinoma, Transitional Cell
2
Interventions
Docetaxel
7
Trastuzumab
3
sargramostim
2
entrectinib
2
Radiotherapy
2
Polymerase Chain Reaction
2
Immunohistochemistry
2
Gene Expression Profiling
2
Fluorodeoxyglucose F18
2
Flow Cytometry
2
Erlotinib Hydrochloride
2
Biopsy
2
zanidatamab
1
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
trastuzumab deruxtecan
1
tipifarnib
1
tanespimycin
1
pertuzumab
1
pembrolizumab
1
oncogene protein E7, Human papillomavirus type 16
1
entinostat
1
alectinib
1
aldesleukin
1
X-Ray Therapy
1
Vorinostat
1
Thalidomide
1
Taxes
1
Ritonavir
1
Quality of Life
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Salivary Gland Neoplasms
×
Drug Therapy
×
Genitourinary
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled